Harrow (HROW) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.46
- Estimate
- -$0.24
- Surprise
- -91.7%
- Revenue (period 2026-06-30)
- $70.7M
- Score today
- 5.2/10
Revenue source: xbrl.
How the report landed
Harrow (HROW) reported a wider loss than forecast — adjusted EPS of -$0.46 against the -$0.24 estimate (a 91.7% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates HROW Sell at 5.2/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -91.7% surprise compares with a -61.5% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Quality below floor (3.3 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $29.87
- Price target
- $54.81
- Stop
- $27.78
- Upside to target
- +83.5%
- Reward-to-risk
- 8.6:1
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
HROW at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.10B
- P/E (fwd)
- 10.6
- 52-week range
- $26.96–$54.85
- Off 52-week high
- 45.5%
- RSI (14)
- 53
- Volume vs avg
- 0.01×
- Score today
- 5.2/10